ERBB2 and triple-negative breast carcinoma: Because dual HER2-targeted therapy has been reported to improve overall survival and progression-free survival compared to single HER2-targeted therapy [61] (reviewed in [62]), we also suggest evaluation of this combinatorial therapy as a treatment for basal-like/triple-negative breast cancer patients.